Cancer drug spartalizumab gets extended safety check in ongoing patients

NCT ID NCT04058756

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 30 times

Summary

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled from earlier Novartis studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Columbia University Medical Center

New York, New York, 10032, United States
MD Anderson Cancer Center Uni of Te

Houston, Texas, 77030, United States
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Guangzhou, 510060, China
Novartis Investigative Site

Brno, 656 53, Czechia
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

High West, Hong Kong
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Pokfulam, 999077, Hong Kong
Novartis Investigative Site

Budapest, H 1122, Hungary
Novartis Investigative Site

Debrecen, 4032, Hungary
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Milan, MI, 20141, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Modena, MO, 41124, Italy
Novartis Investigative Site

Aviano, PN, 33081, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Leiden, South Holland, 2333 ZA, Netherlands
Novartis Investigative Site

Gdansk, 80-952, Poland
Novartis Investigative Site

Poznan, 60-693, Poland
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Providence Portland Medical Center

Portland, Oregon, 97123, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

spartalizumab (PDR001)

What this could lead to

If this trial succeeds, it could provide continued access to spartalizumab for patients who are already benefiting, while gathering long-term safety data.

What could go wrong

This is a small, early-phase rollover study, not designed to prove effectiveness. It only includes patients already doing well on the drug, so results may not apply to a broader population.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS